Unicycive Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Unicycive Therapeutics
UNCY Stock  USD 6.34  0.58  8.38%   
Unicycive Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Unicycive Therapeutics' valuation are provided below:
Market Capitalization
138.6 M
Enterprise Value Revenue
16.632
Earnings Share
(3.44)
We have found one hundred twenty available fundamental trend indicators for Unicycive Therapeutics, which can be analyzed and compared to other ratios and to its competition. All investors should make sure to double-check all of Unicycive Therapeutics current market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. Market Cap is likely to rise to about 50.3 M in 2026, whereas Enterprise Value is likely to drop slightly above 12.8 M in 2026.
Check Unicycive Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Unicycive Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 433.7 K, Interest Expense of 60.7 K or Selling General Administrative of 14.6 M, as well as many indicators such as Price To Sales Ratio of 16.04, Dividend Yield of 0.0165 or PTB Ratio of 6.76. Unicycive financial statements analysis is a perfect complement when working with Unicycive Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Unicycive Stock
Check out the analysis of Unicycive Therapeutics Correlation against competitors.
For more information on how to buy Unicycive Stock please use our How to Invest in Unicycive Therapeutics guide.

Unicycive Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets38.2 M36.4 M8.4 M
Slightly volatile
Short and Long Term Debt Total701.8 K695.7 K936.1 K
Slightly volatile
Other Current Liabilities27.2 M25.9 M5.7 M
Slightly volatile
Total Current Liabilities29.1 M27.7 M7 M
Slightly volatile
Accounts Payable619.3 K1.1 M361.8 K
Slightly volatile
Cash And Short Term Investments31.6 M30.1 M7.7 M
Slightly volatile
Common Stock Shares Outstanding8.1 M7.7 M2.2 M
Slightly volatile
Liabilities And Stockholders Equity38.2 M36.4 M8.4 M
Slightly volatile
Other Current Assets5.8 M5.5 M1.4 M
Slightly volatile
Other Stockholder Equity131.1 M124.9 M29.4 M
Slightly volatile
Total Liabilities29.3 M27.9 M7 M
Slightly volatile
Total Current Assets37.4 M35.6 M8.2 M
Slightly volatile
Short Term Debt617.5 K590.4 K881.6 K
Slightly volatile
Common Stock137.7 K131.1 K45.3 K
Slightly volatile
Common Stock Total Equity9.3 K10.3 K8.5 K
Slightly volatile
Non Current Liabilities Total100 K105.3 K674.3 K
Slightly volatile
Short and Long Term Debt78.7 K82.8 K438.9 K
Pretty Stable
Capital Stock137.7 K131.1 K31.6 K
Slightly volatile
Property Plant Equipment266.4 K299.7 K327.1 K
Slightly volatile

Unicycive Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative14.6 M13.9 M3.9 M
Slightly volatile
Other Operating Expenses38.8 M36.9 M10 M
Slightly volatile
Research Development24.2 M23 M6.1 M
Slightly volatile
Total Operating Expenses38.8 M36.9 M10 M
Slightly volatile
Cost Of Revenue516.8 K492.2 K102.4 K
Slightly volatile
Selling And Marketing Expenses227.2 K255.6 K279 K
Slightly volatile

Unicycive Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation516.8 K492.2 K119.9 K
Slightly volatile
Other Non Cash Items7 M6.7 M2.2 M
Slightly volatile
Capital Expenditures86.9 K82.8 K35.5 K
Slightly volatile
End Period Cash Flow31.6 M30.1 M6.8 M
Slightly volatile
Change To Netincome4.7 M4.4 M1.6 M
Slightly volatile
Stock Based Compensation2.8 M2.7 M714.2 K
Slightly volatile
Begin Period Cash Flow11.7 M11.2 M2.9 M
Slightly volatile
Issuance Of Capital Stock61.2 M58.3 M13.8 M
Slightly volatile
Dividends Paid1.1 M1.3 M916 K
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio16.0428.412.8646
Slightly volatile
Dividend Yield0.01650.01850.0202
Slightly volatile
Stock Based Compensation To Revenue1.492.361.3763
Slightly volatile
Capex To Depreciation0.180.191.6095
Slightly volatile
EV To Sales10.6616.5510.0974
Slightly volatile
Sales General And Administrative To Revenue7.8211.47.9008
Slightly volatile
Research And Ddevelopement To Revenue12.8817.214.018
Slightly volatile
Capex To Revenue0.01680.0160.0056
Slightly volatile
Cash Per Share2.983.512.5499
Slightly volatile
Income Quality0.540.70.675
Pretty Stable
Current Ratio1.341.150.8466
Slightly volatile
Capex Per Share0.01160.01240.0199
Slightly volatile
Revenue Per Share0.50.320.5636
Slightly volatile
Interest Debt Per Share0.140.1260.9479
Slightly volatile
Debt To Assets0.02670.028121.2759
Slightly volatile
Ebt Per Ebit0.931.031.1472
Slightly volatile
Quick Ratio1.341.150.8466
Slightly volatile
Net Income Per E B T0.871.01.0618
Pretty Stable
Cash Ratio1.771.251.2204
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.11.151.0184
Slightly volatile
Fixed Asset Turnover0.930.984.3921
Slightly volatile
Debt Ratio0.02670.028121.2759
Slightly volatile
Price Sales Ratio16.0428.412.8646
Slightly volatile
Asset Turnover0.0520.05470.2699
Slightly volatile

Unicycive Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap50.3 M47.9 M16.4 M
Slightly volatile
Enterprise Value12.8 M25 M10.6 M
Slightly volatile

Unicycive Fundamental Market Drivers

Forward Price Earnings1.2453
Cash And Short Term Investments26.1 M

Unicycive Upcoming Events

29th of March 2024
Upcoming Quarterly Report
View
21st of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
29th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Unicycive Therapeutics Financial Statements

Unicycive Therapeutics investors use historical fundamental indicators, such as Unicycive Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Unicycive Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue-16.2 K-15.4 K
Cost Of Revenue492.2 K516.8 K
Stock Based Compensation To Revenue 2.36  1.49 
Sales General And Administrative To Revenue 11.40  7.82 
Research And Ddevelopement To Revenue 17.20  12.88 
Capex To Revenue 0.02  0.02 
Revenue Per Share 0.32  0.50 
Ebit Per Revenue(35.39)(37.16)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
FSLYFastly Class A
MOBMobilicom Limited American
CMGChipotle Mexican Grill

Additional Tools for Unicycive Stock Analysis

When running Unicycive Therapeutics' price analysis, check to measure Unicycive Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Unicycive Therapeutics is operating at the current time. Most of Unicycive Therapeutics' value examination focuses on studying past and present price action to predict the probability of Unicycive Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Unicycive Therapeutics' price. Additionally, you may evaluate how the addition of Unicycive Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY